MTN-015 was a long-term, observational study that was designed to track the nature of HIV progression and treatment response among women who acquired HIV while taking part in an MTN “parent study” of an ARV-based HIV prevention product. In total, MTN-015 enrolled 479 women from one of four MTN studies (HPTN-035, MTN-003/VOICE, MTN-020/ASPIRE and MTN-025/HOPE), beginning in 2013. Collectively, results suggest there are no differences in the progression of HIV or in the response to treatment (e.g., development of drug resistance) among women who received an ARV-based prevention product and those who received a placebo.
15-August-2016
See Also